Stockscreener 앱 받기
7.93
0.13%
-0.01
전일 마감가:
$7.94
열려 있는:
$7.93
하루 거래량:
1.00M
Relative Volume:
0.53
시가총액:
$548.99M
수익:
-
순이익/손실:
$-30.04M
주가수익비율:
-5.019
EPS:
-1.58
순현금흐름:
$-27.38M
1주 성능:
+0.51%
1개월 성능:
+135.31%
6개월 성능:
+392.55%
1년 성능:
+250.88%
1일 변동 폭
$7.91
$7.95
1주일 범위
$7.89
$8.01
52주 변동 폭
$0.8301
$8.20
Regulus Therapeutics Inc Stock (RGLS) Company Profile
명칭
Regulus Therapeutics Inc
전화
858-202-6300
주소
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
7.93 | 546.26M | 0 | -30.04M | -27.38M | -1.58 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-03-18 | 개시 | Leerink Partners | Outperform |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 개시 | Leerink Partners | Outperform |
| 2017-06-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-06 | 재확인 | Wedbush | Outperform |
| 2017-01-30 | 다운그레이드 | Needham | Buy → Hold |
| 2017-01-30 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 재확인 | Chardan Capital Markets | Buy |
| 2016-11-02 | 재확인 | Needham | Buy |
| 2016-07-25 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | FBR Capital | Outperform |
| 2016-06-28 | 재확인 | Needham | Buy |
| 2016-06-07 | 재확인 | Chardan Capital Markets | Buy |
| 2016-04-13 | 개시 | Chardan Capital Markets | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2015-04-21 | 재개 | FBR Capital | Outperform |
| 2014-11-24 | 개시 | Deutsche Bank | Buy |
| 2014-08-07 | 재확인 | FBR Capital | Outperform |
| 2013-08-14 | 재확인 | Needham | Buy |
모두보기
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus
Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily
Novartis Gains Further Renal Territory With Regulus Acquisition - insights.citeline.com
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (RGLS) - Seeking Alpha
Regulus Therapeutics stock soars on acquisition deal with Novartis By Investing.com - Investing.com Nigeria
Regulus Therapeutics Inc (RGLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):